Compare DCBO & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DCBO | ACHV |
|---|---|---|
| Founded | 2016 | N/A |
| Country | Canada | United States |
| Employees | 900 | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 584.3M | 618.0M |
| IPO Year | 2020 | 2018 |
| Metric | DCBO | ACHV |
|---|---|---|
| Price | $23.18 | $7.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | ★ $32.00 | $14.67 |
| AVG Volume (30 Days) | 103.0K | ★ 1.1M |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.89 | N/A |
| Revenue Next Year | $11.44 | N/A |
| P/E Ratio | $22.04 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.39 | $2.55 |
| 52 Week High | $32.20 | $7.34 |
| Indicator | DCBO | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 63.72 | 73.79 |
| Support Level | $16.54 | $4.04 |
| Resistance Level | $26.48 | N/A |
| Average True Range (ATR) | 1.07 | 0.33 |
| MACD | 0.19 | 0.08 |
| Stochastic Oscillator | 82.03 | 98.71 |
Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.